Table 2. . Preoperative multivariable Cox regression analyses predicting overall survival.
| Variables | Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age cont. | 0.98 | 0.96–1.01 | 0.29 | 0.98 | 0.96–1.01 | 0.26 | 0.98 | 0.95–1.00 | 0.11 |
| Gender (males vs females) | 1.92 | 1.07–3.43 | 0.02 | 1.88 | 1.05–3.36 | 0.03 | 1.92 | 1.07–3.44 | 0.02 |
| BMI cont. | 0.88 | 0.81–0.95 | 0.002 | 0.89 | 0.82–0.96 | 0.005 | 0.9 | 0.83–0.98 | 0.01 |
| Hydronephrosis (no vs yes) | 1.91 | 1.1–3.29 | 0.02 | 1.62 | 0.92–2.84 | 0.09 | 1.7 | 0.97–2.96 | 0.06 |
| Hystology (pure vs nonpure UC) | 0.95 | 0.43–2.06 | 0.89 | 0.92 | 0.42–1.99 | 0.83 | 1.08 | 0.5–2.36 | 0.83 |
| NAC (3 cycles vs >3 cycles) | 1.32 | 0.78–2.23 | 0.29 | 1.3 | 0.77–2.19 | 0.31 | 1.32 | 0.78–2.22 | 0.29 |
| Stage, Tis/T1 | |||||||||
| T2 | 1.78 | 0.7–4.52 | 0.22 | 1.44 | 0.55–3.72 | 0.45 | 1.53 | 0.6–3.9 | 0.36 |
| T3 | 1.98 | 0.73–5.37 | 0.17 | 1.85 | 0.68–5 | 0.22 | 1.98 | 0.74–5.32 | 0.17 |
| T4 | 5.44 | 2.02–14.66 | 0.001 | 4.9 | 1.8–13.32 | 0.002 | 4.83 | 1.79–13.06 | 0.002 |
| Nodes + (no vs yes) | 1.43 | 0.65–3.1 | 0.36 | 1.46 | 0.67–3.17 | 0.32 | 1.26 | 0.58–2.73 | 0.54 |
| Metastasis + (no vs yes) | 1.12 | 0.14–8.56 | 0.9 | 1.02 | 0.13–7.83 | 0.98 | 1.16 | 0.15–8.77 | 0.88 |
| NLR (<3 vs >3) | - | - | - | 1.81 | 1.06–3.09 | 0.02 | - | - | - |
| NPAR (<18 vs >18) | - | - | - | - | - | - | 2.28 | 1.31–3.99 | 0.004 |
| Harrell’s C index | 71.5 | 72.1 | 72.8 | ||||||
Boldface values represent statistical significance.
C index: Concordance index; Cont.: Continued; HR: Hazard ratio; NAC: Neoadjuvant chemotherapy; NLR: Neutrophil-to-lymphocyte ratio; NPAR: Neutrophil percentage-to-albumin ratio; UC: Urothelial cancer.